Valeritas’ V-Go® Wearable Insulin Delivery Device Results in Clinical Benefits Sustained Over Time in Patients with Diabetes
BRIDGEWATER, N.J., May 14, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, announced today the publication last week of a manuscript titled “Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: a Retrospective Analysis” in Advances in Therapy, an international, peer-reviewed journal. The 14-month analysis showed that patients with diabetes benefited from significant and sustained reductions in A1C compared to baseline over time with V-Go use.
“Diabetes is a chronic progressive disease and managing multiple insulin injections can be a constant challenge for patients with diabetes when a basal-bolus insulin regimen is required to reach treatment goals,” said Dr. David Sutton, lead author and Co-Founder, Northeast Florida Endocrine and Diabetes Associates, LLC in Jacksonville, Florida, US. “We are encouraged to see the clinical benefits of V-Go are sustained over time.”
The current study demonstrated V-Go use was associated with improved A1C which was sustained for over a year in 103 patients with diabetes in a real-world setting. Reductions in A1C with V-Go ranged from 1.3 – 1.7% over the course of the study. At baseline, 33% of patients used two or more concomitant medications and, by 14 months this was reduced by more than half to 15% of patients. Therefore, the improvements in A1C seen in the study were not attributable to changes in concomitant non-insulin glucose lowering medications. Further, improvements in A1C were achieved using less insulin. Patients prescribed basal-bolus regimens with conventional insulin delivery at baseline observed a reduction in insulin of nearly 30% after switching to V-Go.
“V-Go provides patients a simpler and more convenient alternative to having to take multiple daily shots in order to deliver basal-bolus insulin and we are pleased to see additional evidence published supporting the benefits of V-Go for insulin delivery in patients with diabetes.” said John Timberlake, President and Chief Executive Officer of Valeritas.
About Valeritas Holdings, Inc.Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.
Investor Contacts:Lynn Pieper Lewis or Greg ChodaczekGilmartin Group610-368-6505 email@example.com
Media Contact:Kevin KnightKnight Marketing Communications, Ltd.(206) 451-4823 firstname.lastname@example.org